Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Gains from Sales and Divestitures (2020 - 2025)

Historic Gains from Sales and Divestitures for Beam Therapeutics (BEAM) over the last 6 years, with Q3 2025 value amounting to $783939.0.

  • Beam Therapeutics' Gains from Sales and Divestitures rose 3625.24% to $783939.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $783939.0, marking a year-over-year increase of 3625.24%. This contributed to the annual value of $1.3 million for FY2024, which is 17730.59% up from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' Gains from Sales and Divestitures is $783939.0, which was up 3625.24% from $688359.0 recorded in Q2 2025.
  • Beam Therapeutics' 5-year Gains from Sales and Divestitures high stood at $1.3 million for Q4 2024, and its period low was $283186.0 during Q1 2022.
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $469531.0 (2023), whereas its average is $558681.9.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first tumbled by 5843.78% in 2022, then skyrocketed by 17730.59% in 2024.
  • Quarter analysis of 5 years shows Beam Therapeutics' Gains from Sales and Divestitures stood at $1.0 million in 2021, then tumbled by 58.44% to $424303.0 in 2022, then increased by 10.66% to $469531.0 in 2023, then surged by 177.31% to $1.3 million in 2024, then plummeted by 39.79% to $783939.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $783939.0 for Q3 2025, versus $688359.0 for Q2 2025 and $607196.0 for Q1 2025.